Back to top

Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Lannett Co (LCI - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Lannett Co is one of 833 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. LCI is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for LCI's full-year earnings has moved 1.67% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the most recent data, LCI has returned 62.50% so far this year. In comparison, Medical companies have returned an average of 10.46%. This shows that Lannett Co is outperforming its peers so far this year.

Looking more specifically, LCI belongs to the Medical - Drugs industry, which includes 175 individual stocks and currently sits at #68 in the Zacks Industry Rank. On average, this group has gained an average of 17.93% so far this year, meaning that LCI is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on LCI as it attempts to continue its solid performance.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Lannett Co Inc (LCI) - free report >>

Published in